Literature DB >> 16040813

Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) phosphorylation at multiple sites in neostriatal neurons.

Miho Hamada1, Joseph P Hendrick, Gregory R Ryan, Mahomi Kuroiwa, Hideho Higashi, Masatoshi Tanaka, Angus C Nairn, Paul Greengard, Akinori Nishi.   

Abstract

Nicotinic acetylcholine receptors (nAChRs) regulate dopaminergic signaling in the striatum by modulating the release of neurotransmitters. We have recently reported that nicotine stimulates the release of dopamine via alpha4beta2(*) nAChRs and/or alpha7 nAChRs, leading to the regulation of DARPP-32 at Thr34, the site involved in regulation of protein phosphatase-1 (PP-1). In this study, we investigated the regulation of DARPP-32 phosphorylation at its other sites, Thr75 [cyclin-dependent kinase-5 (Cdk5) site], Ser97 (CK2 site), and Ser130 (CK1 site), that serve to modulate Thr34 phosphorylation and dephosphorylation. In neostriatal slices, nicotine (100 microM) increased phosphorylation of DARPP-32 at Ser97 and Ser130 at an early time point (30 s) and decreased phosphorylation of DARPP-32 at Thr75 at a late time point (3 min). The increase in Ser97 and Ser130 phosphorylation was mediated through the release of dopamine via activation of alpha4beta2(*) nAChRs and alpha7 nAChRs and the subsequent activation of dopamine D1 and D2 receptors. The decrease in Thr75 phosphorylation was mediated through the release of dopamine via activation of alpha4beta2(*) nAChRs and the subsequent activation of dopamine D1 receptors. These various actions of nicotine on modulatory sites of phosphorylation would be predicted to result in a synergistic increase in the state of phosphorylation of DARPP-32 at Thr34 and thus would contribute to increased dopamine D1 receptor/DARPP-32 Thr34/PP-1 signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040813     DOI: 10.1124/jpet.105.090852

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 2.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

3.  The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury.

Authors:  James W Bales; Hong Q Yan; Xiecheng Ma; Youming Li; Ranmal Samarasinghe; C Edward Dixon
Journal:  Exp Neurol       Date:  2011-03-01       Impact factor: 5.330

4.  Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain.

Authors:  Tara C Tassin; David R Benavides; Florian Plattner; Akinori Nishi; James A Bibb
Journal:  J Biol Chem       Date:  2015-05-13       Impact factor: 5.157

5.  Incubation of nicotine seeking is associated with enhanced protein kinase A-regulated signaling of dopamine- and cAMP-regulated phosphoprotein of 32 kDa in the insular cortex.

Authors:  Amir Abdolahi; Glen Acosta; Florence J Breslin; Scott E Hemby; Wendy J Lynch
Journal:  Eur J Neurosci       Date:  2010-02       Impact factor: 3.386

6.  Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatum.

Authors:  Melissa I Torres-Altoro; Brian N Mathur; Justin M Drerup; Rachel Thomas; David M Lovinger; James P O'Callaghan; James A Bibb
Journal:  J Neurochem       Date:  2011-09-20       Impact factor: 5.372

7.  Glutamate Counteracts Dopamine/PKA Signaling via Dephosphorylation of DARPP-32 Ser-97 and Alteration of Its Cytonuclear Distribution.

Authors:  Akinori Nishi; Miriam Matamales; Veronica Musante; Emmanuel Valjent; Mahomi Kuroiwa; Yosuke Kitahara; Heike Rebholz; Paul Greengard; Jean-Antoine Girault; Angus C Nairn
Journal:  J Biol Chem       Date:  2016-12-20       Impact factor: 5.157

Review 8.  Nicotine and inflammatory neurological disorders.

Authors:  Wen-Hua Piao; Denise Campagnolo; Carlos Dayao; Ronald J Lukas; Jie Wu; Fu-Dong Shi
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

9.  Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice.

Authors:  Ken Koda; Yukio Ago; Toshiyuki Kawasaki; Hitoshi Hashimoto; Akemichi Baba; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2007-10-03       Impact factor: 4.530

10.  A kinetic model of dopamine- and calcium-dependent striatal synaptic plasticity.

Authors:  Takashi Nakano; Tomokazu Doi; Junichiro Yoshimoto; Kenji Doya
Journal:  PLoS Comput Biol       Date:  2010-02-12       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.